AstraZeneca PLC AZN
LSE · United Kingdom · Health Technology
GBp 12,030.00-250.00 (-2.04%)
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
The shares fell more than major US indexes, while Zacks consensus estimates point to lower quarterly earnings and higher revenue.
Summit gained after AstraZeneca agreed to invest $2 billion, while CarMax beat earnings forecasts and FICO faced a new scoring framework.
Investors marked down Olema after AstraZeneca’s SERENA-4 setback raised fresh questions about oral SERD drugs in breast cancer.
Citi says AstraZeneca’s breast cancer setback is manageable as a narrower Etcamah launch and wider pipeline support its valuation.
Seven hundred thousand seniors have already started GLP-1s through Medicare, and AstraZeneca just pushed a once-daily pill into late-stage trials. Before you plan your budget around a $50 copay, there are two deadlines that could change everything.
AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant read ivonescimab correctly.
AI-driven discovery, streamlined approvals and partnerships are accelerating drug repurposing, creating opportunities in oncology, rare, neurodegenerative and infectious diseases.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Drug Repurposing Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global drug repurposing market was valued at US$29.4 billion in 2024 and is projected to reach US$37.3 billion by 2030, expanding at a compound annual growth ra
AstraZeneca (LSE:AZN) reported that the FDA has granted Priority Review to a supplemental Biologics License Application for IMFINZI with enfortumab vedotin in muscle-invasive bladder cancer. The application targets patients who are ineligible for or decline cisplatin-based chemotherapy, a group with limited treatment choices. Priority Review shortens the FDA review timeline for this regimen, reflecting the agency's view that it may offer a meaningful clinical advance. The Priority Review...
AstraZeneca (LSE:AZN) has just filed a New Drug Application with the US FDA for combining ORPATHYS and TAGRISSO in a specific form of advanced non small cell lung cancer after EGFR TKI treatment. AstraZeneca’s latest oncology filings land after a choppy run for the ticker, with the share price down 10.29% over 90 days and 8.56% year to date. At the same time, the 1 year total shareholder return of 13.04% and 5 year total shareholder return of 55.73% point to a still solid longer term story,...
Astrazeneca (AZN) closed at $164.21 in the latest trading session, marking a -1.17% move from the prior day.
Summit Therapeutics stock jumped Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech.
Nvidia fell 0.7%, reversing from Monday’s gains, when it announced a $150 billion expansion to its stock buyback plan and software to tackle the problem of AI safety. Navitas Semiconductor closed flat, erasing earlier gains seen after it received a U.S. Army grant to develop power semiconductor technology. The company has faced a recent slump in its share price, navigating recent quarterly losses and a patent dispute with peer Wolfspeed.
AstraZeneca stock sinks as management announces $2 billion investment in Summit Therapeutics. But should you buy the dip in AZN shares today? Let’s find out!
AstraZeneca's (AZN) $2 billion investment in Summit Therapeutics (SMMT) is a "win-win" and potential
A preferred-equity investment secures collaboration access without the cost and integration risk of an acquisition.
The liquidation auctioneer Liquidity Services is closing in on a buy point. The stock is up roughly 45% this year.
The companies will start by testing ivonescimab with an AstraZeneca ADC in gastrointestinal cancers
SMMT shares jump as AstraZeneca commits $2 billion to accelerate ivonescimab development and expand clinical collaboration.
The deal would give AstraZeneca exposure to a promising cancer treatment without acquiring the company outright.
The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, has won positive responses from UBS and Jefferies after investing $2 billion in Summit Therapeutics and agreeing a cancer drug collaboration. UBS said the investment gives AstraZeneca exposure to the programmed...
Graphwise, a leading provider of AI context platforms, today announced major updates to its AI Context Platform, Graphwise Platform, which include new Adobe integration, built-in evaluation tools, and broader workflow automation features. The new release optimizes the creation of a comprehensive context layer for enterprises, which accelerates the integration of AI into multilingual content and data. With its latest software release, Graphwise now supports its customers more efficiently when tra
Investing.com - U.S. stock index futures hovered around the flatline on Tuesday after soaring bond yields dented Wall Street in the prior session, as investors looked ahead to a fresh batch of economic data.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.